Clinical Trial

Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 27, 2026 (before its estimated June 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 1 non-randomized, open-label, single-dose study of pevifoscorvir sodium (also known as ALG-000184) in participants with severe renal impairment (Part 1), in participants with mild or moderate renal impairment (Optional Part 2) and in participants without renal impairment (Parts 1 and 2), matched for age, body weight and, to the extent possible, for sex.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-06.
Status change: Not Yet Recruiting → Recruiting 2026-02-26
Trial Details
NCT Number NCT07342881
Lead Sponsor Aligos Therapeutics
Conditions Chronic Hepatitis B Infection
Enrollment 30 participants
Start Date 2026-02-20
Primary Completion 2026-06-15 (estimated)
Study Completion 2026-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-27